Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.016
Neutral
RSI(14)
44.138
Neutral
STOCH(KDJ)(9,3,3)
14.874
Sell
ATR(14)
0.084
High Vlolatility
CCI(14)
-44.876
Neutral
Williams %R
65.714
Sell
TRIX(12,20)
0.083
Sell
StochRSI(14)
0.000
Sell
Search
BioXcel Therapeutics Inc
BTAIAdd to Watchlist
1.140USD
-0.070-5.79%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
30.87MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of BioXcel Therapeutics Inc
Currency: USD Updated: 2026-05-15Key Insights
BioXcel Therapeutics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 113 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 12.80.In the medium term, the stock price is expected to trend down.The company has shown average stock market performance over the past month, with weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioXcel Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioXcel Therapeutics Inc Highlights
StrengthsRisks
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Growing
The company is in a growing phase, with the latest annual income totaling USD 642.00K.
Fairly Valued
The company’s latest PE is -0.24, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 4.05M shares, increasing 19.34% quarter-over-quarter.
Held by Howard Marks
Star Investor Howard Marks holds 284.10K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
12.800
Target Price
+957.85%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of BioXcel Therapeutics Inc is 5.67, ranking 148 out of 155 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is low.
Score
Financials
6.10
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.12
Operational Efficiency
2.84
Growth Potential
5.20
Shareholder Returns
7.08
BioXcel Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of BioXcel Therapeutics Inc is 5.84, ranking 135 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is -0.24, which is -98.66% below the recent high of -0.00 and -37462.72% above the recent low of -89.89.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 113/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of BioXcel Therapeutics Inc is 7.20, ranking 109 out of 155 in the Pharmaceuticals industry. The average price target is 12.00, with a high of 38.00 and a low of 1.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
12.800
Target Price
+957.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
BioXcel Therapeutics Inc
BTAI
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of BioXcel Therapeutics Inc is 2.58, ranking 152 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.33 and the support level at 0.98, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.186
Sell
MA10
1.220
Sell
MA20
1.174
Sell
MA50
1.272
Sell
MA100
1.487
Sell
MA200
2.159
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Millennium Management LLC
Mehta (Vimal)
Bioxcel Corp
Armistice Capital LLC
Geode Capital Management, L.L.C.
Abante Asesores Gestión, S.G.I.I.C., S.A.
Qatar Investment Authority
Edward Jones
1
2
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of BioXcel Therapeutics Inc is 2.43, ranking 125 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.32. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.31
VaR
+9.18%
240-Day Maximum Drawdown
+85.00%
240-Day Volatility
+132.51%
Return
Best Daily Return
60 days
+18.27%
120 days
+18.27%
5 years
+85.40%
Worst Daily Return
60 days
-10.40%
120 days
-10.40%
5 years
-63.84%
Sharpe Ratio
60 days
-1.14
120 days
-0.66
5 years
-0.39
Risk Assessment
Maximum Drawdown
240 days
+85.00%
3 years
+99.46%
5 years
+99.82%
Return-to-Drawdown Ratio
240 days
-0.16
3 years
-0.33
5 years
-0.20
Skewness
240 days
+4.33
3 years
+2.66
5 years
+1.83
Volatility
Realised Volatility
240 days
+132.51%
5 years
+126.48%
Standardised True Range
240 days
+22.10%
5 years
+953.91%
Downside Risk-Adjusted Return
120 days
-152.03%
240 days
-152.03%
Maximum Daily Upside Volatility
60 days
+76.75%
Maximum Daily Downside Volatility
60 days
+55.50%
Liquidity
Average Turnover Rate
60 days
+24.84%
120 days
+16.47%
5 years
--
Turnover Deviation
20 days
-97.76%
60 days
-95.08%
120 days
-96.73%
Peer Comparison
Pharmaceuticals
BioXcel Therapeutics Inc
BTAI
4.79 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
